1Leite AZ,Sipahi AM,Dami o AO,et al.Protective effect of metronidazole on uncoupling mitochondrial oxidative phosphorylation induced by NSAID:a new mechanism[].Gut.2001
2Baigent C,Patrono C.Selective COX-2inhibitors:where do we go from here[].The Lancet.2008
3Lanas A,Baron JA,Sandler RS,et al.Peptic ulcer and bleeding events associated with rofecoxib in a3-year colorectal adenoma chemoprevention trial[].Gastroenterology.2007
4Graham DY,Opekun AR,Willingham FF,et al.Visible small-intestinal mucosal injury in chronic NSAID users[].Clinics in Gastroenterology.2005
5Laine L,Smith R,Min K,et al.Systematic review:the lower gastrointestinal adverse effects of non-steroidal anti-in-flammatory drugs[].Alimentary Pharmacology and Therapeutics.2006
6Bresalier RS,Sandler RS,Quan H,et al.Cardiovascular events associatedwith rofecoxib in a colorectal adenoma chemoprevention trial[].The New England Journal of Medicine.2005
7McGettigan,P.,Henry,D.Cardiovascular risk and inhibition of cylcooxygenase: a systematic review of the observational studies of inhibitors of cyclooxygenase-2[].The Journal of The American Medical Association.2006
8Wilcox CM,Allison J,Benzuly K,Borum M,Cryer B,Grosser T,Hunt R,Ladabaum U,Lanas A,Paulus H,Regueiro C,Sandler RS,Simon L.Consensus development conference on the use of nonsteroidal anti-inflammatory agents,including cyclooxygenase-2 enzyme inhibitors and aspirin[].Clinics in Gastroenterology.2006
9Scheiman,J.M.,Fendrick,A.M.Summing the risks of NSAID therapy[].The Lancet.2007
10Zhang W,Doherty M,Leeb BF,et al.EULAR evidence based recommendations for the management of hand osteoarthritis:report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics(ESCISIT)[].Annals of the Rheumatic Diseases.2007
2Hsu L C,Parpk J M,Zhang K,et al.The protein kinase PKR is required for macrophage apoptosis after activation of Toll -like receptor 4[J].Nature,2004,428(6980):341-345.
3Zhang X,Song V,Ci X,et al.Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice[J].Inflamm Res,2008,57 (11):524-529.
4Pil H P,Hong L H,Megan R M,et al.Suppression of lipopo-lysaccharide-stimulated tumor necrosis factor-α production by adiponectin is mediated by transcriptional and podt-transcrip-tional mechanisms[J].J Biol Chem,2008,283(40):26850-26858.
5Mihai G,Netea C A,Nol-Petry M F,et al.Differential requirement for the activation of the inflammasome for processing and release of IL-1β in monocytes and macrophages[J].Blood,2009,113(10):2324-2335.
6Modesto R,Wenbo Z H,Dexter L L,et al.Role of IL-6 in an-giotensin Ⅱ -induced retinal vascular inflammation[J].Invest Ophthalmol Vis Sci,2010,51(3):54-61.
7Chan FK, Lanas A, Scheiman J. et al. Celecoxib versus orneprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet, 2010, 376(9736) : 173-179.
8Schnitzer TJ. American College of Rheumatology. Update of ACR guidelines for ostcoarthritis: role of the coxibs. J Pain Symptom Manage. 2002,23(4 Suppl):S24-S30.
9Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with cclecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. JAMA, 2000; 284(10) : 1247-1255.
10Garcia-Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual nonsteroidal anti inflammatory drugs. Lancet, 1994, 343(8900):769-772.
